Pharmaceutical intermediates
Bempedoic acid Intermediates
1 pharmaceutical intermediate for Bempedoic acid. Indication: Hypercholesterolemia; Dyslipidemia; Heterozygous Familial Hypercholesterolemia (HeFH).
About Bempedoic acid
- Originator
- Esperion Therapeutics Inc
- Indication
- Hypercholesterolemia; Dyslipidemia; Heterozygous Familial Hypercholesterolemia (HeFH)
- Approved Date
- 02/21/2020
- NCE Patent
- 02/21/2025
- DS/DP
- 12/03/2030
Available intermediates
1 intermediate currently listed for Bempedoic acid. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| ethyl-2,2-dimethyl-7-bromoheptanoate | 123469-92-1 | / | / |
Building toward Bempedoic acid?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →